USP-CEU is a competitive and supportive host institution for MSCA-PF candidates, with a strong track record including 10 awarded fellowships, an exceptional 100/100 score, and two recent successes in the MSCA-PF 2025 call. We offer personalised guidance throughout the proposal preparation process, as well as our International Talent Retention Programme, which provides successful MSCA Fellows with an additional 6–12-month contract to support long-term career development.
Hosting Research Group
Our research group, ALLERGY, focuses on the study of immune mechanisms underlying allergic and inflammatory diseases, with particular emphasis on severe phenotypes and translational research. Based at Universidad CEU San Pablo, ALLERGY integrates basic, clinical, and computational approaches to better understand disease pathogenesis and improve patient management.
Our team has strong expertise in biomarker discovery and immune profiling, applying multi-omics technologies and high-dimensional data analysis to advance precision medicine and patient stratification. Their research also explores novel therapeutic strategies, including biologics and immunomodulatory approaches.
The ALLERGY group operates within a highly collaborative framework, maintaining active partnerships with more than 20 hospitals across Spain and international networks such as EAACI. Its multidisciplinary environment combines immunology, bioinformatics, and functional studies, providing an excellent setting for cutting-edge translational research and advanced training.
Publications:
- Bianchini R, et al. Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping Review. Allergy. 2025 Aug 29. doi: 10.1111/all.16672. Epub ahead of print. PMID: 40878618.
- Contreras N, et al. Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab. Allergy. 2024 Dec 18. doi: 10.1111/all.16434. Epub ahead of print. PMID: 39692160.
- Escolar-Peña A, et al. Specific microRNA Profile Associated with Inflammation and Lipid Metabolism for Stratifying Allergic Asthma Severity. Int J Mol Sci. 2024 Aug 30;25(17):9425. doi: 10.3390/ijms25179425. PMID: 39273372
- Couto-Rodriguez A, et al.Platelet-Derived Extracellular Vesicles as Lipid Carriers in Severe Allergic Inflammation. Int J Mol Sci. 2023 Aug 12;24(16):12714.
- Pablo-Torres C, et al. Deciphering the role of platelets in severe allergy by an integrative omics approach. Allergy. 2023 May;78(5):1319-1332. doi: 10.1111/all.15621. Epub ahead of print. PMID: 36527294
Research Project Description
Chronic inflammatory diseases and cancer represent opposite extremes of immune regulation. While inflammatory disorders are characterized by immune hyperactivation, cancer exhibits excessive immune suppression. Understanding the molecular and cellular mechanisms underlying these complementary immune responses could open new avenues for therapeutic interventions and personalized treatments.
Our group proposes an innovative comparative approach between cancer and allergy using existing multi-omics datasets, including transcriptomics, proteomics, metabolomics, and high-dimensional cytometry. Integrative analyses will identify key regulatory pathways, cellular nodes, and potential biomarkers that differentiate hyperactivation from suppression in human immunity. Findings will be validated in vitro and ex vivo using models of T cells, macrophages, and tumor cells to assess plasticity and functional repolarization.
Candidate experience and profile:
Postdoctoral candidates of any nationality (max. 8 years after defense) with with a strong bioinformatics, computational biology, or multidisciplinary biomedical background who can bring new expertise to our group.
Candidates will benefit from collaboration and networking opportunities with over 20 Spanish hospitals and international partners, including the European Academy of Allergy and Clinical Immunology (EAACI).
Application
An expression of interest shall be sent to elena.izquierdoalvarez@ceu.es Your file should contain the following elements:
- A short CV (Max. 2 pages).
- Two letters of reference
For MSCA-PF 26 call, at the deadline for the submission of proposals (09/09/2026) candidates must not have resided or carried out their main activities in Spain for more than 12 months in the 3 years immediately prior to the above mentioned deadline.
Those files received before 15th of June will be considered for MSCA-PF 2026 call. Applications received after this date, will be considered for other calls after discussion with the candidate.
Keywords: Bioinformatics, Multi-omics integration, Allergy, Cancer, Immunology
